Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INM

+ Watchlist+ Portfolio

InMed Pharmaceuticals Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$13.01
52-Week Range
$5.75 – $23.30
Market Cap
$8.55M
P/E (TTM)
—
EPS (TTM)
-27.60
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
-222.07%
Return on Assets
-85.56%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
0.50
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-2.73M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$84.35M

Market Snapshot

About

InMed Pharmaceuticals Inc. is a pharmaceutical company developing novel therapies through the research and development of cannabinoid-based medications. The company focuses on diseases with high unmet medical needs, including epidermolysis bullosa, a rare genetic skin disorder, and glaucoma. InMed has developed proprietary biosynthesis technology to manufacture pharmaceutical-grade cannabinoids at commercial scale, reducing reliance on traditional plant-based extraction. The company's pipeline includes both topical and ocular drug candidates targeting specific medical conditions where cannabinoids may provide therapeutic benefits.